Verona Pharma Plc (VRNA)

Verona Pharma Stock Analysis & Ratings


VRNA Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.41 - $14.69
Previous Close$12.48
Average Volume (3M)880.16K
Market CapN/A
Enterprise ValueN/A
P/E Ratio-13.8
Next EarningsNov 08, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score10
EPS (TTM)-0.90
Shares Outstanding60,368,048
Standard Deviation0.16
10 Day Avg. Volume96,293
30 Day Avg. Volume880,162
P/B Ratio2.68
P/S Ratio8.33
P/CF RatioN/A
P/FCF Ratio-37.30
Total Debt$1.13M
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside94.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Verona Pharma’s price range in the past 12 months?
Verona Pharma lowest stock price was $3.41 and its highest was $14.69 in the past 12 months.
    What is Verona Pharma’s market cap?
    Currently, no data Available
    What is Verona Pharma’s price target?
    The average price target for Verona Pharma is $22.67. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
    The highest analyst price target is $25.00 ,the lowest forecast is $20.00. The average price target represents 94.93% Increase from the current price of $11.63.
      What do analysts say about Verona Pharma?
      Verona Pharma’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
        When is Verona Pharma’s upcoming earnings report date?
        Verona Pharma’s upcoming earnings report date is Nov 08, 2022 which is in 83 days.
          How were Verona Pharma’s earnings last quarter?
          Verona Pharma released its earnings results on Aug 09, 2022. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.217 by $0.177.
            Is Verona Pharma overvalued?
            According to Wall Street analysts Verona Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
              Does Verona Pharma pay dividends?
              Verona Pharma does not currently pay dividends.
              What is Verona Pharma’s EPS estimate?
              Verona Pharma’s EPS estimate is -$0.09.
                How many shares outstanding does Verona Pharma have?
                Verona Pharma has 73,354,170 shares outstanding.
                  What happened to Verona Pharma’s price movement after its last earnings report?
                  Verona Pharma reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.217. Following the earnings report the stock price went up 44.317%.
                    Which hedge fund is a major shareholder of Verona Pharma?
                    Among the largest hedge funds holding Verona Pharma’s share is Aisling Capital Management LP. It holds Verona Pharma’s shares valued at 6M.


                      Verona Pharma Stock Analysis

                      Smart ScoreOutperform
                      The Verona Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Verona Pharma Plc

                      Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. Its lead product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis